--- title: "Eli Lilly receives FDA approval for its Alzheimer’s drug Kinsula" description: "Eli Lilly has received FDA approval for its Alzheimer's drug, Kinsula, expanding treatment options for the neurological disorder. The approval is a major breakthrough for Eli Lilly, as the drug had be" type: "news" locale: "en" url: "https://longbridge.com/en/news/207847647.md" published_at: "2024-07-03T04:57:15.000Z" --- # Eli Lilly receives FDA approval for its Alzheimer’s drug Kinsula > Eli Lilly has received FDA approval for its Alzheimer's drug, Kinsula, expanding treatment options for the neurological disorder. The approval is a major breakthrough for Eli Lilly, as the drug had been previously rejected due to insufficient data. With the growing number of Alzheimer's patients and the potential market demand, this news could have a significant impact on Eli Lilly's stock. Eli Lilly & Co (NYSE: LLY) received approval for its Alzheimer’s drug from the Food & Drug Administration on Tuesday. The development is significant as it expands treatment options for the neurological disorder that affects close to 7 million Americans. At the time of writing, Eli Lilly shares are exchanging hands at $910. The pharma stock has gained more than 50% since the start of 2024. ## Is Kinsula news significant for Eli Lilly stock? Alzheimer’s is among the top five causes of deaths for Americans aged more than 65. More importantly, the number of patients suffering from this mind-wasting disease is expected to hit 13 million in the United States by 2050, which underscores the urgent need for effective treatments like Lilly’s donanemab. Securing FDA approval for its Alzheimer’s drug is a major breakthrough for Eli Lilly. That’s because the U.S. regulator cited insufficient data as it rejected donanemab last year. The approval faced unexpected delay in March of 2024 as well. The Alzheimer’s news may unlock the next leg up in Eli Lilly stock that has outperformed this year on the back of strong demand for its weight-loss drug. Many expect LLY to be the first healthcare name to hit $1.0 trillion in valuation. ## Lilly to compete directly with Biogen FDA’s full approval for Lilly’s Alzheimer’s drug arrives shortly after its advisory panel concluded the benefits of donanemab outweigh the risks. The $870 billion behemoth will now compete directly with Biogen that secured approval for Leqembi (its Alzheimer’s drug) in summer of 2023. Donanemab is set to become the third treatment for Alzheimer’s to hit the market in the U.S. Both Leqembi and Donanemab are monoclonal antibodies that target amyloid plaques. Neither is a definitive cure and both can have potential safety concerns including brain swelling and bleeding that can sometimes be fatal. Three patients, for example, in the late-stage study of Eli Lilly died due to ARIA (amyloid-related imaging abnormalities). Watch here: https://www.youtube.com/embed/gO2ShFRucNM?feature=oembed ## Other recent developments related to LLY Note that Eli Lilly will market its Alzheimer’s drug as “Kisunla”.In June, former FDA commissioner Dr Scott Gottlieb said Alzheimer’s could be a very big category for LLY. The donanemab news arrives a couple weeks after the New York listed firm announced $1.30 a share of dividend for the third quarter. It also teamed up with OpenAI last month to tap on artificial intelligence to discover novel medicines and treat drug-resistant bacteria. Brad Lightcap – the chief operating officer of LLY said at the time: > Advanced AI has the potential to deliver innovative breakthroughs in pharma, and we’re committed to working together with industry leaders to deliver tangible benefits for patients. The post Eli Lilly receives FDA approval for its Alzheimer's drug Kinsula appeared first on Invezz ### Related Stocks - [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026 | Eli Lilly's stock is surging due to AI deals and a favorable drug pricing agreement. The healthcare sector, particularly | [Link](https://longbridge.com/en/news/267579204.md) | | Eli Lilly joins a very exclusive club | Eli Lilly becomes the eleventh company to surpass $1 trillion in market capitalization, marking a milestone for healthca | [Link](https://longbridge.com/en/news/267672421.md) | | Tempus AI EVP Erik Phelps Sells Shares | Erik Phelps, EVP and Chief Admin. Officer of Tempus AI, sold 9,464 shares of Class A Common Stock on February 19, 2026, | [Link](https://longbridge.com/en/news/276495655.md) | | Annette Franqui Purchases 1,540 Shares of OFG Bancorp (NYSE:OFG) Stock | OFG Bancorp Director Annette Franqui purchased 1,540 shares of the company's stock at $42.06 per share, totaling $64,772 | [Link](https://longbridge.com/en/news/276494822.md) | | ConocoPhillips considers selling Permian assets worth $2 billion, Bloomberg News reports | Feb 20 (Reuters) - ConocoPhillipsis exploring a sale of some of its Permian Basin assets as part of a broader streamlini | [Link](https://longbridge.com/en/news/276478732.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.